Canakinumab Study in Individuals With Newly Diagnosed Type 1 Diabetes

• Status: Completed
• Trial end date: 2013-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Canakinumab is a fully human anti-interleukin-1β (anti-IL-1β) monoclonal antibody (IgG-1 class). Canakinumab is designed to bind to human IL-1β and to functionally neutralize the bioactivity of this pro-inflammatory cytokine.

The study is a two-arm, multicenter, randomized, double-masked, placebo-controlled clinical trial. 66 subjects will be randomly assigned to receive either monthly subcutaneous injections of 2.0 mg/kg Canakinumab, or placebo for 12 months. All groups will receive standard intensive diabetes treatment with insulin and dietary management.

Participants randomly assigned to Canakinumab treatment or placebo will receive a total of 12 injections over one year.

All subjects will be followed for 1 year of treatment plus 1- 3 years of additional follow-up until study end. Enrollment is expected to occur over two years.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• Treatments: Antibodies, Monoclonal

Criteria

Inclusion Criteria:

• Between the ages of 6-45 years

• Be within 3-months (100 days) of diagnosis of type 1 diabetes

• Must have at least one diabetes-related autoantibody present

• Must have stimulated C-peptide levels >0.2 pmol/ml measured during a mixed meal tolerance test (MMTT) conducted at least 21 days from diagnosis and within 37 days of randomization

• If participant is female with reproductive potential, she must be willing to avoid pregnancy and have a negative pregnancy test during the 12 months of treatment and for an additional 3 months after completing treatment

• Be at least one month from time of last live immunization received

• Willing to forgo live vaccinations for 24 months

• Must be willing to comply with intensive diabetes management

• Must weigh at least 20 kg (44 lbs) at study entry

Exclusion Criteria:

• Are immunodeficient or have clinically significant chronic lymphopenia (low white blood cell count)

• Have an active infection

• Have a positive PPD test result

• Be currently pregnant or lactating, or anticipate getting pregnant

• Ongoing use of medications known to influence glucose tolerance

• Require use of other immunosuppressive agents

• Have serologic evidence of current or past HIV, Hepatitis B, or Hepatitis C infection

• Have any complicating medical issues or abnormal clinical laboratory blood counts or results that interfere with study conduct; history of malignancies

• Be currently participating in another type 1 diabetes treatment study